The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately

Lemtrada Stroke Lawsuit News

The EU's leading health authority is doing everything short of recalling Lemtrada in order to study the drug's adverse side effects more thoroughly and establish a new risk/reward profile

Saturday, May 4, 2019 - Lemtrada is used to treat relapsing-remitting multiple sclerosis (RRMS), a disease that destroys the protective outer casing surrounding the nerve cells causing seizures. RRMS patients have seizures at interment times that increase in frequency and severity over time until eventually, the seizures occur non-stop. Lemtrada is a highly toxic drug with potentially life-threatening side effects that include immediate and paralyzing stroke and should be used only in the direst cases of the RRMS and when all alternative treatments have failed. National Lemtrada stroke attorneys are offering a free consultation to families and individuals that have suffered from Lemtrada side effects before filing a lawsuit claim.

On April 12, 2019, the European Medicines Agency has opened an investigation concerning complaints against those using the anti Multiple Sclerosis seizure drug Lemtrada (alemtuzumab). The action is in response to Europe's Regulatory Affairs Professional Society reports that Lemtrada patients are reporting "immune-mediated conditions and problems with the heart and blood vessels (leading to strokes) of those taking the medicine, including deaths." While Lemtrada is not under recall it is, however, recommended that MS doctors only use it in very extreme and highly active cases of relapsing-remitting multiple sclerosis. Doctors must have attempted at least two other alternative drug therapies and failed in order to justify accepting the risks Lemtrada poses. The EMA safety committee recommended that Sanofi, maker of Lemtrada, immediately update the product warning label on the drug's packaging to include the following conditions caused by the drug: "immune-mediated conditions, including autoimmune hepatitis (with damage to the liver) and haemophagocytic lymphohistiocytosis (overactivation of the immune system which may affect different parts of the body); problems with the heart and blood vessels occurring within 1-3 days of receiving the medicine, including bleeding in the lungs, heart attack, stroke, cervicocephalic arterial dissection (tears in the lining of the arteries in the head and neck); severe neutropenia (low levels of neutrophils, a type of white blood cell that fights infections)." The EMA states that doctors should monitor patients before, during and immediately after giving a patient a Lemtrada infusion for signs of the above conditions.

The EMA urges physicians to warn potential Lemtrada patients that there have been recent cases of adverse effects of taking Lemtrada "including some affecting the heart, blood vessels, lungs, and liver." Lemtrada patients have complained of chest pain, difficulty breathing, bleeding lungs resulting in coughing up blood, signs of a stroke such as a "drooping of the face, sudden severe headache, weakness on one side, difficulty with speech or neck pain," yellow skin or eyes, dark urine, and bleeding or bruising more easily than normal indicating a liver problem.

On November 29, 2018, the US Food and Drug Administration (FDA) shocked the Multiple Sclerosis treatment community when the agency issued a warning that the Lemtrada (alemtuzumab) causes tears in the lining of the arteries leading to their heart and brain shortly after taking the drug and causes strokes and heart attacks respectively. Alemtuzumab is also sold under the brand names Campath, MabCampath and Campath-1H, The FDA warns that the side effects of the drug could include loss of mental capacity, physical paralysis or death.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.